Modulation of the Human T Cell Response by a Novel Non-Mitogenic Anti-CD3 Antibody
暂无分享,去创建一个
[1] C. Chen,et al. Novel CD3‐specific antibody induces immunosuppression via impaired phosphorylation of LAT and PLCγ1 following T‐cell stimulation , 2014, European journal of immunology.
[2] Aaron J. Martin,et al. Manipulating T cell-mediated pathology: targets and functions of monoclonal antibody immunotherapy. , 2013, Clinical immunology.
[3] Chen Chen,et al. Inhibition of T cell activation through down-regulation of TCR-CD3 expression mediated by an anti-CD90 Ab. , 2011, Immunology letters.
[4] P. van Endert,et al. Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance , 2011, Science Translational Medicine.
[5] K. Herold,et al. Anti‐CD3 mAbs for treatment of type 1 diabetes , 2009, Diabetes/metabolism research and reviews.
[6] J. Shimizu,et al. In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules. , 2008, Immunology letters.
[7] B. Scallon,et al. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody. , 2006, International immunopharmacology.
[8] B. Bisikirska,et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. , 2005, The Journal of clinical investigation.
[9] S. Popma,et al. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells. , 2005, International immunopharmacology.
[10] L. Chatenoud. Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation. , 2004, Current opinion in pharmacology.
[11] A. Weiss,et al. Jurkat T cells and development of the T-cell receptor signalling paradigm , 2004, Nature Reviews Immunology.
[12] J. Bluestone,et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala) , 2003 .
[13] J. Bluestone,et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). , 2003, The Journal of clinical investigation.
[14] P. Parren,et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. , 2000, Cellular immunology.
[15] J. Phillips,et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. , 1999, Transplantation.
[16] C. Anasetti,et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. , 1999, Transplantation.
[17] P. Allen,et al. Molecular basis for the lack of T cell proliferation induced by an altered peptide ligand. , 1998, International immunology.
[18] R. Schwartz,et al. Models of T Cell Anergy: Is There a Common Molecular Mechanism? , 1996 .
[19] A. Necker,et al. Reactivity of mouse T-cell hybridomas expressing human Vbeta gene segments with staphylococcal and streptococcal superantigens , 1996, Infection and immunity.
[20] Paul M. Allen,et al. Partial T cell signaling: Altered phospho-ζ and lack of zap70 recruitment in APL-induced T cell anergy , 1994, Cell.
[21] J. Davoust,et al. Evidence for protein tyrosine kinase involvement in ligand-induced TCR/CD3 internalization and surface redistribution. , 1994, Journal of immunology.
[22] J. Bluestone,et al. A NON‐ACTIVATING “HUMANIZED” ANTI‐CD3 MONOCLONAL ANTIBODY RETAINS IMMUNOSUPPRESSIVE PROPERTIES IN VIVO , 1994, Transplantation.
[23] C. Geisler,et al. CD3 gamma contains a phosphoserine‐dependent di‐leucine motif involved in down‐regulation of the T cell receptor. , 1994, The EMBO journal.
[24] C. Janeway,et al. Signals and signs for lymphocyte responses , 1994, Cell.
[25] S. D. Gorman,et al. The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties , 1993, European journal of immunology.
[26] C. Ferran,et al. IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION: SYSTEMIC CYTOKINE RELEASE AND MODULATION BY CORTICOSTEROIDS , 1990, Transplantation.
[27] P. Vereerstraeten,et al. RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN‐2, AND GAMMA‐INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTS , 1989, Transplantation.
[28] J. Bluestone,et al. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. , 1989, Journal of immunology.
[29] D. Droz,et al. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. , 1986, Transplantation.
[30] M. Crumpton,et al. Activators of protein kinase C down-regulate and phosphorylate the T3/T-cell antigen receptor complex of human T lymphocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[31] T. Mak,et al. Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer , 1985, Nature.
[32] A. Weiss,et al. Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line , 1984, The Journal of experimental medicine.
[33] R. Colvin,et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. , 1981, Transplantation.
[34] R. Colvin,et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. , 1981, The New England journal of medicine.